ELREXFIO 40 mg/mL solution for injection

DRUG4 trials

Sponsors

Intergroupe Francophone Du Myelome, Vaestra Goetalandsregionen, Region Hovedstaden, Fundacion PETHEMA

Conditions

Haematological diseases; any disorder that primarily affects the bloodMultiple MyelomaMultiple myelomaRelapsed/refractory multiple myelomabone marrowthe lymphatic system and/or blood-forming organs.

Phase 2

A multicenter prospective trial estimating the persistence of remission after stopping BCMA-CD3 bispecific antibody in multiple myeloma patients with major M-spike response by use MaldiTOF-based high sensitivity monitoring

Not yet recruitingCTIS2025-524022-18-00

Vaestra GoetalandsregionenMultiple myeloma

Target: 200Updated: 2026-02-16

Multicenter, open label, phase II clinical trial evaluating the combination of elranatamab with mezigdomide and dexamethasone in patients with relapsed/refractory multiple myeloma

Not yet recruitingCTIS2026-526352-31-00

Fundacion PETHEMARelapsed/refractory multiple myeloma

Target: 60Updated: 2026-10-13

Phase 3

A phase 3, open-label, controlled, randomized study of newly diagnosed multiple myeloma treatment, designed to evaluate the efficacy and safety of the elranatamab-lenalidomide combination as a replacement for chemotherapy followed by autologous stem cell transplant in the consolidation phase, and to compare elranatamab with standard of care in the maintenance phase (ElLen; IFM 2025-01)

RecruitingCTIS2024-516418-39-00

Intergroupe Francophone Du MyelomeMultiple Myeloma

Start: 2025-07-09Target: 824Updated: 2025-12-15

Phase 4

A multicentre, adaptive, randomised, multidomain, platform trial for dose optimization in the treatment of adult patients with haematological diseases (BLOOD-dose): core protocol

Not yet recruitingCTIS2026-525658-13-00

Region Hovedstadenbone marrow, Haematological diseases; any disorder that primarily affects the blood, the lymphatic system and/or blood-forming organs.

Target: 200Updated: 2026-06-25